Adagene Inc. (ADAG) News
Follow Adagene Inc. (ADAG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Adagene to start Phase 1 study of ADG138 in Q4 2026
Adagene said it will begin a Phase 1 study of ADG138 for advanced solid tumors in Q4 2026.
EQUITY | Sep 22, 2026, 12:43 PM UTC
M
Adagene gets NMPA IND clearance for ADG138
Adagene received NMPA clearance for the IND of ADG138, a double-masked HER2×CD3 T-cell engager, with a Phase 1 study in advanced solid tumors expected to start in China in Q4 2026.
REGULATION | Sep 22, 2026, 12:04 PM UTC
L
Adagene names Third Arc Bio’s first lead candidate under amended collaboration
Adagene said Third Arc Bio selected a first lead candidate under an amended strategic collaboration. The amendment includes a transition to an integrated asset and technology partnership.
MNA | Sep 10, 2026, 12:04 PM UTC
L
ADAG - Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Maske
ADAG - Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
EQUITY | Sep 10, 2026, 12:00 PM UTC
L
Adagene initiated at Buy by Chardan Capital
EQUITY | Sep 10, 2026, 11:57 AM UTC
L
Adagene and Exelixis reach milestone in SAFEbody ADC collaboration
Adagene announced it achieved a milestone in its ongoing collaboration with Exelixis to advance SAFEbody antibody-drug conjugate candidates.
GEOPOLITICS | Sep 09, 2026, 12:01 PM UTC
L
Adagene milestone in collaboration with Exelixis on SAFEbody ADC candidates
Adagene says it achieved a milestone in its collaboration with Exelixis to advance SAFEbody antibody-drug conjugate candidates.
EQUITY | Sep 09, 2026, 12:00 PM UTC
L
Adagene to participate in three upcoming investor conferences
Adagene says it will participate in three upcoming investor conferences; no catalyst or additional details were supplied.
REGULATION | Aug 20, 2026, 12:00 PM UTC
M
Adagene Reports Six Months 2026 Financial Results
Adagene reports six months 2026 financial results and provides corporate updates
EQUITY | Aug 12, 2026, 11:30 AM UTC